• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this document? Why not share!

Curriculum Vitale

on

  • 539 views

 

Statistics

Views

Total Views
539
Views on SlideShare
539
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Curriculum Vitale Curriculum Vitale Document Transcript

    • Heather Wakelee, M.D. Assistant Professor Department of Medicine, Division of Oncology Stanford University Stanford Clinical Cancer Center 875 Blake Wilbur Drive Stanford, CA 94305-5826 (650) 736-7221 hwakelee@stanford.edu Education 1992 A.B. in Molecular Biology, Magna cum laude Princeton University, Princeton, New Jersey, 1996 M.D., Johns Hopkins University School of Medicine, Baltimore, Maryland Postgraduate Training 1996.97 Internship in Internal Medicine Stanford University School of Medicine, Stanford, California 1997.99 Residency in Internal Medicine Stanford University School of Medicine, Stanford, California 1999-00 Chief Residency in Internal Medicine Stanford University School of Medicine, Stanford, California 2000.3 Fellowship in Medical Oncology Stanford University School of Medicine, Stanford, California 2002 AACR/ASCO Joint Workshop, Methods in Clinical Cancer Research Vail, Colorado, July 27- August 2, 2002 Academic/Clinical Appointments 2003.4 Staff Physician, Division of Oncology Stanford University School of Medicine, Stanford, California 2004 -06 Clinical Instructor, Division of Oncology Stanford University School of Medicine, Stanford, California 2006 Assistant Professor of Medicine, Division of Oncology Stanford University School of Medicine, Stanford, California Honors 1992 Sigma Xi 1996 Alpha Omega Alpha 1999-00 Chief Resident, Stanford Department of Internal Medicine 2003 American Society of Clinical Oncology Merit Award Recipient 2005 Women Against Lung Cancer Travel Grant Award – 11th World Conference on Lung Cancer 2/1/05 1
    • Board Certification 1999 American Board of Internal Medicine, Internal Medicine 2003 American Board of Internal Medicine, Medical Oncology Licensure 1997 California, A63195 National Committees 2005- American Society of Clinical Oncology – Scientific Program Committee – Lung Cancer Track, 2005 - 2004 - American Society of Clinical Oncology – Oncology Compendium Project 2004 -2006 Education Committee Lung Cancer Track, 2004 - 2002 - Eastern Cooperative Oncology Group (ECOG) Thoracic Core Committee 2006 - International Association for the Study of Lung Cancer (IASLC) World Congress 2009 Local Organizing Committee Chair – Fellows Day University Committees 2005- Cancer Center Research Database Committee– Core Development Member 2005 - Disease Management Committee– Thoracic Oncology Team Leader 2006- Cancer Center Clinical Trial Design and Biostatistics Committee 2006- Stanford Faculty Senate alternate member 2006- Course Director of MED 322A, Medical Oncology Clinics at Stanford University School of Medicine Professional Societies American Association for Cancer Research (AACR) American Society of Clinical Oncology (ASCO) International Association for the Study of Lung Cancer (IASLC) National Lung Cancer Partnership (formerly Women Against Lung Cancer) Editorial Positions Current Treatment Options in Oncology (section editor, lung cancer 2005-) Peer-Reviewer American Journal of Clinical Oncology, Cancer, Clinical Cancer Research, Clinical Lung Cancer, Core Evidence, Drugs & Aging, Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer Chemotherapy and Pharmacology 2
    • Peer-Reviewed Publications 1. Haws CM, Nepomuceno IB, Krouse ME, Wakelee H, Law T, Xia Y, Nguyen H, Wine JJ. delta-F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. American Journal of Physiology 270 (Cell Physiology 39): C1544-C1555, 1996. 2. Wakelee H, Ramalingam S, Belani CP. Docetaxel in advanced non-small cell lung cancer. Expert Review of Anticancer Therapy. Vol 5 (1):13-24, 2005. 3. Wakelee H, Fisher GA. A Phase I Trial of Irinotecan (CPT-11) with Amifostine in Patients with Metastatic Colorectal Cancer. Investigational New Drugs. Vol 23 (3):241-2, 2005. 4. Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH, for the Eastern Cooperative Oncology Group. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer. Vol 48 (3):389-397, 2005. 5. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. A Phase II Study of IFOX Therapy (Gefitinib, 5-Fluorouracil, Leucovorin, Oxaliplatin) in Previously Treated Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology. Vol 23 (24):5613-9, 2005. 6. Wakelee HA, Sikic BI. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. Clinical Lung Cancer. Vol 7 (Suppl 1):S6-12, 2005. 7. Wakelee HA, Schiller JH. Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clinical Lung Cancer. Vol 7 (Suppl 1):S31-8, 2005. 8. Le Q-T, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O’bryne KJ, Koong AC, Giaccia AJ. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clinical Cancer Research. Vol 12 (5):1507-12, 2006. 9. Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Changes in the Natural History of Non-Small Cell Lung Cancer (NSCLC): Comparison of Outcome and Patient Characteristics in Advanced NSCLC Patients Entered in Eastern 3
    • Cooperative Oncology Group (ECOG) Trials from 1981-1990 versus 1991-2000. Cancer. Vol 106(10):2208-17, 2006. 10. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. Journal of Thoracic Oncology Vol 1 (5):441-446, 2006. 11. Cabebe E, Wakelee H. Sunitinib – A newly approved small molecule inhibitor of angiogenesis. Drugs of Today (Barcelona). Vol 42(6):387-398, 2006. 12. Donington JS, Le QT, Wakelee HA. Lung cancer in women: Exploring sex differences in susceptibility, biology and therapeutic response. Clinical Lung Cancer Vol 8(1):22-9, 2006. 13. Roy MS, Le Q-T, Donington JS, Wakelee HA. A multi-disciplinary approach to management in a patient with bilateral superior sulcus non-small cell lung carcinoma. Clinical Lung Cancer Vol 8(2):146-8, 2006. 14. Le Q-T, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, Kee ST, Constantinescu D, Whyte RI, Donington J. Results of a phase I dose escalation study using single fraction stereotactic radiotherapy for lung tumors. Journal of Thoracic Oncology Vol 1(8):802-9, 2006. 15. Wakelee HA, Chang ET, Gomez SL, Keegan THM, Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, West DW. Lung cancer incidence in never-smokers. Journal of Clinical Oncology Vol 25(5):472-478, 2007. 16. Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for non-small cell lung cancer -How to handle stage I disease. The Oncologist. (in press) Other Publications 1. Wakelee H, Kelly K. Novel approaches for the treatment of small cell lung cancer. Hematology/Oncology Clinics of North America. Vol 18 (2):499-518, 2004. 2. Alberts, WM, Vaporciyan AA, Wakelee H. Turning the tide: New directions for the treatment of early stage non-small cell lung cancer. American Thoracic Society Newsletter. July:1-12, 2005. 3. Wakelee H, Polsdorfer R. Adjuvant Chemotherapy in NSCLC. Bay Area Oncology News. Vol 1 (3):6-9, 2005. 4. Kumar A, Wakelee H. Second-and third-line treatments in non-small cell lung cancer. Current Treatment Options in Oncology. Vol 7 (1):37-49, 2006. 4
    • 5. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. The Oncologist. Vol 10 (suppl 3):1-10, 2005. 6. Wakelee H, Gandara DR. North American cooperative group research efforts in lung cancer. Syrigos KN, Nutting CM, Roussos, C (eds) Tumors of the Chest: Biology, Diagnosis and Management. Germany: Springer-Verlag, 2006;451-461. 7. Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the new intergroup trial. Clinical Lung Cancer Vol 8(1):18-21, 2006. 8. Cabebe E, Wakelee H. Adjuvant and neoadjuvant treatment in early stage non- small-cell lung cancer. Sandler AB (eds) New Treatment Paradigms in Non-Small- Cell Lung Cancer. Manhasset, New York: CMPMedica, 2006:1-25. 9. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC. Current Treatment Options in Oncology. (in press) 10. Gandara DR, Wakelee H, Calhoun R, Jablons D. Adjuvant Chemotherapy of stage I non-small cell lung cancer in North America. Journal of Thoracic Oncology. (in press). Abstracts 1. Wakelee H, Fisher G. A Phase I Trial of Irinotecan (CPT-11) in Combination with Amifostine in Patients with Metastatic Colorectal Cancer. Proceedings of the American Society of Clinical Oncology 20:122b, 2001 (abstract 2238). 2. Cho CD, Fisher GA, Halsey J, Jambalos CN, Advani RH, Wakelee H, Lum BL, Sikic BI. A phase II study of gefitinib (ZD1839, IressaTM) in combination with FOLFOX-4 (IFOX) in patients with unresectable or metastatic colorectal cancer. Proceedings of the American Society of Clinical Oncology 22:265, 2003 (abstract 1062). Poster Discussion Session. 3. Jacobs C, Wakelee H, Loewen G, Berg K, Rowinsky E, Hammond L, Chu Q, Schindler K, Flanagan S, Takimoto C. Phase I pharmacokinetic (PK) study of bexarotene in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology 22:696, 2003 (abstract 2798). 4. Wakelee H, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH, for the Eastern Cooperative Oncology Group. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIa non-small cell lung cancer (NSCLC) leads to higher than expected risk of death from intercurrent disease (DID). Proceedings of the American Society of Clinical Oncology 22:633, 2003 (abstract 2545). Poster Discussion Session. 5
    • 5. Fisher GA, Kuo T, Cho CD, Halsey J, Jambalos CN, Schwartz EJ, Robert RV, Advani RH, Wakelee HA. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Proceedings of the American Society of Clinical Oncology 23:249, 2004 (abstract 3514). Poster Discussion Session. 6. Le Q-T, Ho A, Cotrutz C, Wakelee H, Kee ST, Donington J, Whyte RI. Single fraction stereotactic radiosurgery (SFSR) for lung tumors – A phase I dose escalation trial. Proceedings of the American Society of Clinical Oncology 23:670, 2004 (abstract 7231). Poster presentation. 7. Tolcher AW, Wakelee H, Mita M, Fitzgerald AM, Hill M, Fox NL, Howard T, Corey A, Sikic B. A phase I clinical trial of HGS-ETR2, a fully-human monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors. Proceedings of the American Association for Cancer Research 46, 2005 (abstract 543). Poster presentation. 8. Wakelee H, Adjei AA, Keer H, Halsey J, Hanson L, Reid J, Hutchison S, Piens J, Lacy S, Sikic BI. A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies. Journal of Clinical Oncology – 2005 American Society of Clinical Oncology Annual Meeting Proceedings 23(16S):227s, 2005 (abstract 3142). 9. West HJ, Belt R, Wakelee H, Bloss L, Taylor L, Monberg M, Ye Z, Obasaju C. Pemetrexed (P) Plus Gemcitabine (G) as Front-line Chemotherapy for Patients (Pts) with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): A Phase II Clinical Trial. Journal of Clinical Oncology – 2005 American Society of Clinical Oncology Annual Meeting Proceedings 23(16S):649s, 2005 (abstract 7117). Poster presentation. 10. Fisher G, Advani R, Wakelee H, Jacobs C, Gladysheva K, Fitzgerald A, Sikic B. A Phase I trial of Oblimersen and Gemcitabine in refractory and advanced malignancies. Journal of Clinical Oncology – 2005 American Society of Clinical Oncology Annual Meeting Proceedings 23(16S):234s, 2005 (abstract 3174). 11. Advani R, Gordon M, Hurwitz H, Mendelson D, Wakelee H, Ebbinghaus S, Hoch U, Silverman J, Havrilla N, Adelman D. Phase I trial of SNS-595 in patients with advanced malignancies. Journal of Clinical Oncology – 2005 American Society of Clinical Oncology Annual Meeting Proceedings 23(16S):159s, 2005 (abstract 2099). 12. Wakelee H, Wang W, Schiller J, Langer C, Sandler A, Belani C, Johnson D. Survival differences by gender for patients with advanced non-small cell lung 6
    • cancer in Eastern Cooperative Oncology Group trial 1594. Lung Cancer 49 (suppl 2):S22, 2005 (abstract O-056). Oral presentation. 13. Wakelee H, Middleton G, Dunlop D, Kelly C, Ramlau R, Leighl N, Hao D, Zatloukal P, Loewen G, Cox K, Jacobs C. Effect of bexarotene on vinorelbine and cisplatin pharmacokinetics (PK) during a Phase I study in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 49 (suppl 2):S274, 2005 (abstract P-592). Poster presentation. 14. Wakelee H, Adjei AA, Halsey J, Lensing J, Dugay J, Hanson L, Reid J, Hutchison S, Piens J, Sikic BI. A Phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics:122, 2005 (abstract A261). Poster presentation. 15. Advani A, Gordon M, Hurwitz H, Mendelson D, Wakelee H, Ebbinghaus S, Hoch U, Silverman J, Havrilla N, Adelman D. Phase I trial of SNS-595 in patients (pts) with advance malignancies. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics:151, 2005 (abstract B100). Poster presentation. 16. Sarantopoulos J, Wakelee H, Mita M, Fitzgerald AM, Hill M, Fox NL, Howard T, Ullrich S, Tolcher AW, Sikic BI. HGS-ETR2-ST02: A phase I clinical trial of HGS- ETR2, a fully- human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics:202, 2005 (abstract C21). Poster presentation. 17. Patnaik A, Wakelee H, Mita M, Fitzgerald AM, Hill M, Fox NL, Howard T, Ullrich S, Tolcher A, Sikic B. HGS-ETR2: A fully human monoclonal antibody to TRAIL- R2: Results of a phase I trial in patients with advanced solid tumors. Journal of Clinical Oncology – 2006 American Society of Clinical Oncology Annual Meeting Proceedings 24(18S):123s, 2006 (abstract 3012). Oral presentation (Clinical Science Symposium). 18. Wakelee HA, Adjei AA, Halsey J, Lensing JL, Dugay JD, Hanson LJ, Reid JM, Piens JR, Sikic BI. A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). Journal of Clinical Oncology – 2006 American Society of Clinical Oncology Annual Meeting Proceedings 24(18S):131s, 2006 (abstract 3044). Poster discussion session. 19. Hurwitz H, Gordon M, Advani R, Ebbinghaus S , Mendelson D, Wakelee H, Hoch U, Silverman J, Havrilla N, Adelman D. SNS-595 demonstrates clinical activity and 7
    • dose-proportional pharmacokinetics (PK) in two phase I clinical trials. Journal of Clinical Oncology – 2006 American Society of Clinical Oncology Annual Meeting Proceedings 24(18S):136s, 2006 (abstract 3062). Poster presentation. 20. West HJ, Belt RJ, Wakelee HA, Monberg MJ, Frye LA, Ye Z, Obasaju CK. PFront line therapy with gemcitabine (G) administered immediately prior to pemetrexed (P) for patients (Pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical trial. . Journal of Clinical Oncology – 2006 American Society of Clinical Oncology Annual Meeting Proceedings 24(18S):393s, 2006 (abstract 7116). Poster presentation. Invited Presentations (10 of 50) 1. “Chemotherapy and Integration of Novel Agents in Early-Stage NSCLC.” Presented as part of the session “Turning the Tide: New Directions for the Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)” at the American Thoracic Society 100th International Conference in San Diego, CA, May 24, 2005. 2. “Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: A New Standard of Care.” Presented at Stanford University Department of Medicine Grand Rounds, August 11, 2005. 3. Session Chair of the Thoracic Tumor Board at the 8th annual Northern California Tumor Board at Silverado presented by Stanford University School of Medicine. Napa, California, March 10, 2006. 4. “Women and Lung Cancer.” Presented at The 3rd Annual Clinical Update in Adult Medicine at Stanford University, Stanford, CA March 31, 2006. 5. “Mapatumumab (HGS-ETR1) and Lexatumumab (HGS-ETR2): TRAIL Receptor Agonist Monoconal Antibodies, A New Approach to Cancer Therapy. Presented as part of the “Emerging Agents in Lung Cancer” Workshop at the 7th International Lung Cancer Congress in Maui, HI, June 28, 2006. 6. “Gender Differences in NSCLC: Rationale for Ongoing Studies.” Presented at the 7th International Lung Cancer Congress in Maui, HI, July 1, 2006. 7. “Recurrent Disease: Chemotherapy and Novel Treatments”. Presented at the Dr Richard Shapiro Memorial Oncology Symposium 2006 “Advances in Lung Cancer Treatment” in Santa Cruz, CA, September 30, 2006. 8. “First Line NSCLC: Chemotherapy & Novel Treatments” and “Adjuvant Chemotherapy in NSCLC.” Presented as part of the “Challenging Cases in Lung Cancer” by NMCR in San Francisco, CA, October 14, 2006. 8
    • 9. “Novel Broad-Spectrum Kinase Inhibitors” presented as part of the “Third Annual Symposium on The Future of Lung Cancer, a Translational Focus” conference in Washington, DC, December 2, 2006. 10. “XL647” presented at the 7th Annual Targeted Therapies for the Lung Cancer Conference in Santa Monica, CA, February 23, 2007. 9